The gutebrain axis in obesity

Best Practice and Research: Clinical Gastroenterology

Volumn 28, Issue 4, 2014, Pages 559-571

  Buhmann, Helena ^a   Le Roux, Carel W ^b,c   Bueter, Marco ^a,d  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Appetite; Gastrointestinal hormones; Glucagon like peptide 1 (GLP 1); Hypothalamus; Obesity

Indexed keywords

AMYLIN; CHOLECYSTOKININ; FATTY ACID; FRUCTOSE; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUTAMIC ACID; HORMONE RECEPTOR; OXYNTOMODULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY; SEROTONIN; GASTROINTESTINAL HORMONE;

APPETITE; ARCUATE NUCLEUS; ARTICLE; BODY WEIGHT; BRAIN; CENTRAL NERVOUS SYSTEM; DIETARY INTAKE; EATING; FEEDING BEHAVIOR; FOOD INTAKE; HUMAN; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; HYPOTHALAMUS VENTROMEDIAL NUCLEUS; INTESTINE; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; WEIGHT CONTROL; WEIGHT REDUCTION; GASTROINTESTINAL TRACT; GLUCAGON-LIKE-PEPTIDE 1 (GLP-1); HYPOTHALAMUS; METABOLISM; PHYSIOLOGY; REVIEW;

APPETITE; GASTROINTESTINAL HORMONES; GLUCAGON-LIKE-PEPTIDE 1 (GLP-1); HYPOTHALAMUS; OBESITY;

APPETITE REGULATION; BRAIN; GASTROINTESTINAL HORMONES; GASTROINTESTINAL TRACT; HUMANS; OBESITY;

EID: 84910003898     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2014.07.003     Document Type: Review

References (143)

1. Allison DB, Saunders SE. Obesity in North America. An overview. Med Clin North Am 2000;84:305-32.
2. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 2004;291:2847-50.
3. Visscher TL, Seidell JC. The public health impact of obesity. Annu Rev Public Health 2001;22:355-75.
4. Baretic M. Obesity drug therapy. Minerva Endocrinol 2013;38:245-54.
5. Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther 2014;95:53-66.
6. Kushner RF. Weight loss strategies for treatment of obesity. Prog Cardiovasc Dis 2014;56:465-72.
7. Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007;357:753-61.
8. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007;357:741-52.
9. Borg CM, le Roux CW, Ghatei MA, Bloom SR, Patel AG, Aylwin SJ. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 2006;93:210-5.
10. le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007;246:780-5.
11. Naslund E, Gryback P, Hellstrom PM, Jacobsson H, Holst JJ, Theodorsson E, et al. Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 1997;21:387-92.
12. Bueter M, le Roux CW. Sir David Cuthbertson Medal Lecture. Bariatric surgery as a model to study appetite control. Proc Nutr Soc 2009;68:227-33.
13. Schwartz MW, Woods SC, Porte Jr D, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404:661-71.
14. Cone RD, Cowley MA, Butler AA, FanW, Marks DL, Low MJ. The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord 2001;25(Suppl. 5):S63-7.
15. Suzuki K, Jayasena CN, Bloom SR. Obesity and appetite control. Exp Diabetes Res 2012;2012:824305.
16. Mayer J, Thomas DW. Regulation of food intake and obesity. Science 1967;156:328-37.
17. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004;116:337-50.
18. Murphy KG, Bloom SR. Gut hormones and the regulation of energy homeostasis. Nature 2006;444:854-9.
19. Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo H, et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 2002;123:1120-8.
20. van der Kooy D. Area postrema: site where cholecystokinin acts to decrease food intake. Brain Res 1984;295:345-7.
21. Grill HJ, Smith GP. Cholecystokinin decreases sucrose intake in chronic decerebrate rats. Am J Physiol 1988;254:R853-6.
22. Ellacott KL, Halatchev IG, Cone RD. Interactions between gut peptides and the central melanocortin system in the regulation of energy homeostasis. Peptides 2006;27:340-9.
23. Schwartz MW, Woods SC, Seeley RJ, Barsh GS, Baskin DG, Leibel RL. Is the energy homeostasis system inherently biased toward weight gain? Diabetes 2003;52:232-8.
24. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995; 332:621-8.
25. Brady LS, Smith MA, Gold PW, Herkenham M. Altered expression of hypothalamic neuropeptide mRNAs in foodrestricted and food-deprived rats. Neuroendocrinology 1990;52:441-7.
26. Murakami N, Hayashida T, Kuroiwa T, Nakahara K, Ida T, Mondal MS, et al. Role for central ghrelin in food intake and secretion profile of stomach ghrelin in rats. J Endocrinol 2002;174:283-8.
27. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes 2001;50:2540-7.
28. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001;86:5992.
29. Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004;110:3674-9.
30. Nagaya N, Itoh T, Murakami S, Oya H, Uematsu M, Miyatake K, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest 2005;128:1187-93.
31. Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:2832-6.
32. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001;50:1714-9.
33. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000;407:908-13.
34. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346:1623-30.
35. English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JP. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 2002;87:2984.
36. le Roux CW, Patterson M, Vincent RP, Hunt C, Ghatei MA, Bloom SR. Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. J Clin Endocrinol Metab 2005;90:1068-71.
37. Chen HY, Trumbauer ME, Chen AS, Weingarth DT, Adams JR, Frazier EG, et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology 2004;145:2607-12.
38. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, et al. A role for ghrelin in the central regulation of feeding. Nature 2001;409:194-8.
39. Gibbs J, Young RC, Smith GP. Cholecystokinin elicits satiety in rats with open gastric fistulas. Nature 1973;245:323-5.
40. Holt J, Antin J, Gibbs J, Young RC, Smith GP. Cholecystokinin does not produce bait shyness in rats. Physiol Behav 1974;12: 497-8.
41. Rehfeld JF. Clinical endocrinology and metabolism. Cholecystokinin. Best Pract Res Clin Endocrinol Metab 2004;18: 569-86.
42. Geary N. Endocrine controls of eating: CCK, leptin, and ghrelin. Physiol Behav 2004;81:719-33.
43. Kopin AS, Mathes WF, McBride EW, Nguyen M, Al-Haider W, Schmitz F, et al. The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. J Clin Invest 1999;103:383-91.
44. West DB, Fey D, Woods SC. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am J Physiol 1984;246:R776-87.
45. Fong TM. Advances in anti-obesity therapeutics. Expert Opin Investig Drugs 2005;14:243-50.
46. Kim GW, Lin JE, Valentino MA, Colon-Gonzalez F, Waldman SA. Regulation of appetite to treat obesity. Expert Rev Clin Pharmacol 2011;4:243-59.
47. Asakawa A, Inui A, Yuzuriha H, Ueno N, Katsuura G, Fujimiya M, et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 2003;124:1325-36.
48. Batterham RL, le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003;88:3989-92.
49. Clark JT, Kalra PS, CrowleyWR, Kalra SP. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 1984;115:427-9.
50. Asakawa A, Inui A, Kaga T, Katsuura G, Fujimiya M, Fujino MA, et al. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 2003;52:947-52.
51. Balasubramaniam A, Mullins DE, Lin S, Zhai W, Tao Z, Dhawan VC, et al. Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar affinity. J Med Chem 2006;49:2661-5.
52. Lassmann V, Vague P, Vialettes B, Simon MC. Low plasma levels of pancreatic polypeptide in obesity. Diabetes 1980;29: 428-30.
53. Berntson GG, Zipf WB, O'Dorisio TM, Hoffman JA, Chance RE. Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome. Peptides 1993;14:497-503.
54. Tatemoto K, Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 1980;285:417-8.
55. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985;89:1070-7.
56. li-Rachedi A, Varndell IM, Adrian TE, Gapp DA, Van NS, Bloom SR, et al. Peptide YY (PYY) immunoreactivity is co-stored with glucagon-related immunoreactants in endocrine cells of the gut and pancreas. Histochemistry 1984;80:487-91.
57. Oesch S, Ruegg C, Fischer B, Degen L, Beglinger C. Effect of gastric distension prior to eating on food intake and feelings of satiety in humans. Physiol Behav 2006;87:903-10.
58. le Roux CW, Batterham RL, Aylwin SJ, Patterson M, Borg CM, Wynne KJ, et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 2006;147:3-8.
59. Chelikani PK, Haver AC, Reidelberger RD. Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. Endocrinology 2005;146:879-88.
60. Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005;129:1430-6.
61. Koegler FH, Enriori PJ, Billes SK, Takahashi DL, Martin MS, Clark RL, et al. Peptide YY(3-36) inhibits morning, but not evening, food intake and decreases body weight in rhesus macaques. Diabetes 2005;54:3198-204.
62. Tschop M, Castaneda TR, Joost HG, Thone-Reineke C, Ortmann S, Klaus S, et al. Physiology: does gut hormone PYY3-36 decrease food intake in rodents? Nature 2004;430:1.
63. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002;418:650-4.
64. cuna-Goycolea C, van den Pol AN. Peptide YY(3-36) inhibits both anorexigenic proopiomelanocortin and orexigenic neuropeptide Y neurons: implications for hypothalamic regulation of energy homeostasis. J Neurosci 2005;25: 10510-9.
65. Abbott CR, Small CJ, Kennedy AR, Neary NM, Sajedi A, Ghatei MA, et al. Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake. Brain Res 2005;1043:139-44.
66. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstemhypothalamic pathway. Brain Res 2005;1044:127-31.
67. Batterham RL, Cohen MA, Ellis SM, le Roux CW, Withers DJ, Frost GS, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003;349:941-8.
68. Korner J, Bessler M, Cirilo LJ, Conwell IM, Daud A, Restuccia NL, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 2005;90: 359-65.
69. Stock S, Leichner P, Wong AC, Ghatei MA, Kieffer TJ, Bloom SR, et al. Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. J Clin Endocrinol Metab 2005;90:2161-8.
70. Adrian TE, Savage AP, Bacarese-Hamilton AJ, Wolfe K, Besterman HS, Bloom SR. Peptide YY abnormalities in gastrointestinal diseases. Gastroenterology 1986;90:379-84.
71. El-Salhy M, Mazzawi T, Gundersen D, Hatlebakk JG, Hausken T. The role of peptide YY in gastrointestinal diseases and disorders (review). Int J Mol Med 2013;31:275-82.
72. Di FV, Zamboni M, Dioli A, Zoico E, Mazzali G, Omizzolo F, et al. Delayed postprandial gastric emptying and impaired gallbladder contraction together with elevated cholecystokinin and peptide YY serum levels sustain satiety and inhibit hunger in healthy elderly persons. J Gerontol A Biol Sci Med Sci 2005;60:1581-5.
73. Holst JJ. On the physiology of GIP and GLP-1. Horm Metab Res 2004;36:747-54.
74. Larsen PJ, Tang-Christensen M, Jessop DS. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 1997;138:4445-55.
75. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-57.
76. Yamato E, Ikegami H, Takekawa K, Fujisawa T, Nakagawa Y, Hamada Y, et al. Tissue-specific and glucose-dependent expression of receptor genes for glucagon and glucagon-like peptide-1 (GLP-1). Horm Metab Res 1997;29:56-9.
77. Feinle C, Chapman IM, Wishart J, Horowitz M. Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men. Peptides 2002;23:1491-5.
78. Fukase N, Igarashi M, Takahashi H, Manaka H, Yamatani K, Daimon M, et al. Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients. Diabet Med 1993;10:44-9.
79. Verdich C, Toubro S, Buemann B, Lysgard MJ, Juul HJ, Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satietyeeffect of obesity and weight reduction. Int J Obes Relat Metab Disord 2001;25: 1206-14.
80. Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999;48: 86-93.
81. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2:1300-4.
82. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001;281:E155-61.
83. Gutzwiller JP, Goke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999;44:81-6.
84. O'Shea D, Gunn I, Chen X, Bloom S, Herbert J. A role for central glucagon-like peptide-1 in temperature regulation. Neuroreport 1996;7:830-2.
85. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69-72.
86. Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004;127:546-58.
87. Cohen MA, Ellis SM, le Roux CW, Batterham RL, Park A, Patterson M, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003;88:4696-701.
88. Dakin CL, Small CJ, Park AJ, Seth A, Ghatei MA, Bloom SR. Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol Endocrinol Metab 2002;283:E1173-7.
89. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 2004;145:2687-95.
90. Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005;54:2390-5.
91. Druce MR, Minnion JS, Field BC, Patel SR, Shillito JC, Tilby M, et al. Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogs. Endocrinology 2009;150:1712-22.
92. Heppner KM, Habegger KM, Day J, Pfluger PT, Perez-Tilve D, Ward B, et al. Glucagon regulation of energy metabolism. Physiol Behav 2010;100:545-8.
93. Jones BJ, Tan T, Bloom SR. Minireview: glucagon in stress and energy homeostasis. Endocrinology 2012;153:1049-54.
94. Geary N, Kissileff HR, Pi-Sunyer FX, Hinton V. Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men. Am J Physiol 1992;262:R975-80.
95. Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 2009;58:2258-66.
96. Creutzfeldt W, Ebert R, Willms B, Frerichs H, Brown JC. Gastric inhibitory polypeptide (GIP) and insulin in obesity: increased response to stimulation and defective feedback control of serum levels. Diabetologia 1978;14:15-24.
97. Salera M, Giacomoni P, Pironi L, Cornia G, Capelli M, Marini A, et al. Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus, and obesity. J Clin Endocrinol Metab 1982;55:329-36.
98. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002;8:738-42.
99. Ding WG, Gromada J. Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucosedependent insulinotropic polypeptide. Diabetes 1997;46:615-21.
100. Lutz TA, Geary N, Szabady MM, Del PE, Scharrer E. Amylin decreases meal size in rats. Physiol Behav 1995;58:1197-202.
101. Lutz TA. Amylinergic control of food intake. Physiol Behav 2006;89:465-71.
102. Chaudhri OB, Wynne K, Bloom SR. Can gut hormones control appetite and prevent obesity? Diabetes Care 2008;31(Suppl. 2):S284-9.
103. Bailey RJ, Walker CS, Ferner AH, Loomes KM, Prijic G, Halim A, et al. Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes. Br J Pharmacol 2012;166:151-67.
104. Woods SC, Lutz TA, Geary N, LanghansW. Pancreatic signals controlling food intake; insulin, glucagon and amylin. Philos Trans R Soc Lond B Biol Sci 2006;361:1219-35.
105. Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 2004;12:661-8.
106. Polonsky KS, Given BD, Van CE. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988;81:442-8.
107. Air EL, Benoit SC, Blake Smith KA, Clegg DJ, Woods SC. Acute third ventricular administration of insulin decreases food intake in two paradigms. Pharmacol Biochem Behav 2002;72:423-9.
108. Menendez JA, Atrens DM. Insulin and the paraventricular hypothalamus: modulation of energy balance. Brain Res 1991; 555:193-201.
109. Schwartz MW, Sipols AJ, Marks JL, Sanacora G, White JD, Scheurink A, et al. Inhibition of hypothalamic neuropeptide Y gene expression by insulin. Endocrinology 1992;130:3608-16.
110. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-5.
111. Jequier E. Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci 2002;967:379-88.
112. Saad MF, Riad-Gabriel MG, Khan A, Sharma A, Michael R, Jinagouda SD, et al. Diurnal and ultradian rhythmicity of plasma leptin: effects of gender and adiposity. J Clin Endocrinol Metab 1998;83:453-9.
113. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269:540-3.
114. Sahu A. Leptin signaling in the hypothalamus: emphasis on energy homeostasis and leptin resistance. Front Neuroendocrinol 2003;24:225-53.
115. Blevins JE, Baskin DG. Hypothalamic-brainstem circuits controlling eating. Forum Nutr 2010;63:133-40.
116. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996;84:491-5.
117. Halaas JL, Boozer C, Blair-West J, Fidahusein N, Denton DA, Friedman JM. Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci U S A 1997;94:8878-83.
118. Flier JS. Clinical review 94: what's in a name? In search of leptin's physiologic role. J Clin Endocrinol Metab 1998;83: 1407-13.
119. Meldrum BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr 2000;130: 1007S-15S.
120. Kondoh T, Mallick HN, Torii K. Activation of the gut-brain axis by dietary glutamate and physiologic significance in energy homeostasis. Am J Clin Nutr 2009;90:832S-7S.
121. Cintra DE, Ropelle ER, Moraes JC, Pauli JR, Morari J, Souza CT, et al. Unsaturated fatty acids revert diet-induced hypothalamic inflammation in obesity. PLoS One 2012;7:e30571.
122. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature 2006;443:289-95.
123. Halford JC, Harrold JA. 5-HT(2C) receptor agonists and the control of appetite. Handb Exp Pharmacol 2012:349-56.
124. Bello NT, Liang NC. The use of serotonergic drugs to treat obesityeis there any hope? Drug Des Devel Ther 2011;5: 95-109.
125. Martin C, Passilly-Degrace P, Gaillard D, Merlin JF, Chevrot M, Besnard P. The lipid-sensor candidates CD36 and GPR120 are differentially regulated by dietary lipids in mouse taste buds: impact on spontaneous fat preference. PLoS One 2011; 6:e24014.
126. Degrace-Passilly P, Besnard P. CD36 and taste of fat. Curr Opin Clin Nutr Metab Care 2012;15:107-11.
127. Shin YK, Egan JM. Roles of hormones in taste signaling. Results Probl Cell Differ 2010;52:115-37.
128. Young RL, Sutherland K, Pezos N, Brierley SM, Horowitz M, Rayner CK, et al. Expression of taste molecules in the upper gastrointestinal tract in humans with and without type 2 diabetes. Gut 2009;58:337-46.
129. Young RL. Sensing via intestinal sweet taste pathways. Front Neurosci 2011;5:23.
130. Ruiz-Grande C, Alarcon C, Merida E, Valverde I. Lipolytic action of glucagon-like peptides in isolated rat adipocytes. Peptides 1992;13:13-6.
131. Villanueva-Penacarrillo ML, Marquez L, Gonzalez N, az-Miguel M, Valverde I. Effect of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res 2001;33:73-7.
132. Todd JF, Edwards CM, Ghatei MA, Mather HM, Bloom SR. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. Clin Sci (Lond) 1998;95:325-9.
133. Vilsboll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003;88:220-4.
134. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100.
135. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28:1083-91.
136. Zhang YJ, Shen LL, Cheon HG, Xu YN, Jeong JH. Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists. Arch Pharm Res 2014;37:588-99.
137. Cegla J, Tan TM, Bloom SR. Gut-brain cross-talk in appetite regulation. Curr Opin Clin Nutr Metab Care 2010;13:588-93.
138. Powell AG, Apovian CM, Aronne LJ. New drug targets for the treatment of obesity. Clin Pharmacol Ther 2011;90:40-51.
139. Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM, et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005;146:5120-7.
140. Clemmensen C, Chabenne J, Finan B, Sullivan L, Fischer K, Kuchler D, et al. GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes 2014;63:1422-7.
141. Neary NM, McGowan BM, Monteiro MP, Jesudason DR, Ghatei MA, Bloom SR. No evidence of an additive inhibitory feeding effect following PP and PYY 3-36 administration. Int J Obes (Lond) 2008;32:1438-40.
142. Field BC, Wren AM, Peters V, Baynes KC, Martin NM, Patterson M, et al. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 2010;59:1635-9.
143. Vincent RP, le Roux CW. Changes in gut hormones after bariatric surgery. Clin Endocrinol (Oxf) 2008;69:173-9.